Genetic Variations in Attention Deficit Hyperactivity Disorder Subtypes and Treatment Resistant Cases.
- Author:
Dilek UNAL
1
;
Mehmet Fatih UNAL
;
Mehmet ALIKASIFOGLU
;
Arda CETINKAYA
Author Information
- Publication Type:Original Article
- Keywords: ADHD; ADRA2A; COMT; Genetics; Phenotype
- MeSH: Appointments and Schedules; Attention Deficit Disorder with Hyperactivity*; Catechol O-Methyltransferase; Diagnosis; Genetic Variation*; Genetics; Humans; Logistic Models; Mental Disorders; Methylphenidate; Mood Disorders; Parents; Phenotype; Polymorphism, Single Nucleotide; Receptors, Adrenergic, alpha-2; Schizophrenia; Social Class; Trail Making Test; Weights and Measures
- From:Psychiatry Investigation 2016;13(4):427-433
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: ObjectiveaaWe evaluated the distribution of alpha-2A adrenergic receptor (ADRA2A) and catechol-o-methyltransferase (COMT) single nucleotide polymorphisms (SNPs) among ADHD subtypes and other homogeneous patient populations including treatment-resistant cases and patients with high symptom severity. METHODS: Methodsaa121 ADHD patients aged 6-18 years were included in the study. Diagnosis and subtypes designation were confirmed using the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) and symptoms were evaluated using the Conners' Parent (CPRS) and Teacher Rating Scales (CTRS). The response to methylphenidate was assessed objectively using the Clinical Global Impression-Severity Scale (CGI-S) and Global Assessment of Functioning Scale (GAS) as well as the Continuous Performance (CPT) and Trail Making tests (TMT-A, B). Patients were genotyped for ADRA2A (rs1800544) and COMT (rs4680) SNPs by PCR/RFLP and compared to a gender-matched control group. RESULTS: Although there was no association of COMT (rs4680) SNP with symptoms or diagnosis, the ADRA2A polymorphism, low socioeconomic status (SES), and comorbid psychiatric diagnosis were all associated with poor response to methylphenidate in logistic regression analysis. CONCLUSION: Clinicians may consider adjuvant strategies when these negative factors are present to increase the success of tailored ADHD treatments in the future.
